Literature DB >> 1816187

Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.

J W Mouton1, M F Michel.   

Abstract

The pharmacokinetics and penetration into suction blister fluid of meropenem was investigated after intermittent (10 mg/kg/6 h) and during continuous infusion (10 mg/kg/6 h) in eight healthy male volunteers in a crossover fashion. Concentrations in serum, urine and blister fluid were determined by a HPLC method. The pharmacokinetic parameters in serum (+/- S.D.) T1/2 beta, AUC and clearance after the third dose of intermittent infusion were 62.7 (11.4) min, 43.5 (7.1) mg.h/L and 292.1 (36.8) mL/min respectively. The penetration in blister fluid was rapid and good, with a AUC ratio blister fluid/serum of 84.7 (11.4)%. During continuous infusion, from 12 to 18 h after the start of the infusion, the mean concentration in serum was 6.3 (0.7, S.D.) mg/L and in blister fluid 5.4 (0.7, S.D.) mg/L. The clearance was 338.3 (45.6) mL/min for serum. Urinary recovery was 61.6 (8.7)% after intermittent and 61.9 (6.9)% after continuous infusion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1816187     DOI: 10.1093/jac/28.6.911

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.

Authors:  Dana Maglio; Renli Teng; Per T Thyrum; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 3.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

5.  Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.

Authors:  A A Firsov; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

Authors:  Wolfgang A Krueger; Jurgen Bulitta; Martina Kinzig-Schippers; Cornelia Landersdorfer; Ulrike Holzgrabe; Kurt G Naber; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 7.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 9.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

10.  Pharmacokinetics of meropenem in patients with intra-abdominal infections.

Authors:  A Bedikian; M P Okamoto; R K Nakahiro; J Farino; P N Heseltine; M D Appleman; A E Yellin; T V Berne; M A Gill
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.